Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Mar 19;6(3):433–447. doi: 10.1038/s42255-024-00997-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 3 — a, Lifespan assessment in N2 worms treated with or without NR as designed in Fig. 2a (log-rank test, n = 90 animals per group). b, NAD⁺ levels (% control) in D1 adult N2 worms treated with NAD⁺ precursors from embryo stage (One-way ANOVA, mean ± s.e.m, n = 6–8 biological replicates per group). c, mRNA levels by qPCR of genes regulating mitochondrial function in N2 worms treated with NR from Day 1 to Day 2 of adulthood (unpaired two-tailed Student’s t-test, mean ± s.e.m, n = 6 biological replicates per group). d, Seahorse-based oxygen consumption of L4 stage N2 worms from the Fig. 3f. e, Additional integrity scoring parameters of GFP-labeled muscle fibers in the worms from the Fig. 3g (One-way ANOVA, mean ± s.e.m, n = 6 animals, 9–31 sarcomeres per group). f, Lifespan of N2 worms treated with vehicle or trigonelline starting from Day 4 of adulthood (log-rank test, n = 90 animals per group). g, Percentage of paralyzed aged N2 worms (D11=Day 11) after vehicle or trigonelline treatment started at Day 4 of adulthood (n = 3 independent experiments, unpaired two-tailed Student’s t-test, mean ± s.e.m). h, Lifespan in N2 worms treated with or without NA or trigonelline and fed with control (empty vector; e.v.) or nrpt-1 RNAi constructs from Day 1 of adulthood (comparing NA-treated worms to e.v., log-rank test, n = 100 animals per group). i, Lifespan in N2 worms treated with or without NA or trigonelline and fed with control (e.v.) or sir-2.1 RNAi from Day 1 of adulthood (comparing NA-treated worms to e.v., log-rank test, n = 100 animals per group). j, sir-2.1 mRNA levels by qPCR in D1 adult N2 worms fed with control (e.v.) or sir-2.1 RNAi from embryo stage (unpaired two-tailed Student’s t-test, mean ± s.e.m, n = 8 biological replicates per group). k, sirtuin mRNA levels in N2 worms from publicly available RNA seq data⁴⁴ (n = 9 replicates per group). l, NAD⁺ levels (% control) in D1 adult N2 worms treated with trigonelline from embryo stage and fed with control (e.v.) or sir-2.1 RNAi constructs (One-way ANOVA, mean ± s.e.m, n = 6 biological replicates per group). P: <0.05 (*); < 0.01 (**); < 0.001 (***); < 0.0001 (****); n.s., non-significant. For all the individual p values, see the Extended Data Fig. 3 Source file.

Source data